Evidence map›Paper›PMID 40470125›Full record

ArticleCJC pediatric and congenital heart disease2025

Stable Longitudinal Quality of Life in the SERVE Trial Among Adults With Transposition of the Great Arteries and a Systemic Right Ventricle.

Alessandro Castiglione, Markus Schwerzmann, Judith Bouchardy, Ronny Ralf Buechel, Reto Engel, Michael Freese, Harald Gabriel, Matthias Greutmann, Dik Heg, Christian Mueller and 10 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CJC pediatric and congenital heart disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03049540 (Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03049540 phase3completednot on this map

Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial

TypeinterventionalSponsorInsel Gruppe AG, University Hospital BernRan2017 to 2021Enrolled100ConditionsHeart Defects, Congenital, Transposition of Great Vessels With Ventricular InversionArmsTadalafil 20 MG, Placebo 20 MG
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Alessandro CastiglioneDepartment of Cardiology, Center for Congenital Heart Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Markus SchwerzmannDepartment of Cardiology, Center for Congenital Heart Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Judith BouchardyDepartment of Cardiology and Cardiac Surgery (CHUV), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Ronny Ralf BuechelDepartment of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Zurich, Switzerland.
Reto EngelDepartment of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Michael FreeseDepartment of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, Basel, Switzerland.
Harald GabrielDepartment of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Matthias GreutmannUniversity Heart Center, Department of Cardiology, University of Zurich, Zurich, Switzerland.
Dik HegDepartment of Clinical Research, University of Bern, Bern, Switzerland.
Christian MuellerDepartment of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, Basel, Switzerland.
Mathias PossnerDepartment of Cardiology, Center for Congenital Heart Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Francisco Javier Ruperti-RepiladoDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Tobias RutzDepartment of Cardiology and Cardiac Surgery (CHUV), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Jurg SchwitterCardiac MR Center of the University Hospital Lausanne and CMR Corelab (swissCVIcorelab, CHUV), Lausanne, Switzerland.
Corina ThometDepartment of Cardiology, Center for Congenital Heart Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Daniel ToblerDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Matthias WilhelmUniversity Clinic of Cardiology, Preventive Cardiology and Sports Medicine, Inselspital, University Hospital, Bern, Switzerland.
Kerstin WustmannDepartment of Cardiology, Center for Congenital Heart Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Fabienne SchwitzDepartment of Cardiology, Center for Congenital Heart Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
SERVE trial

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Adults with a transposition anatomy and a systemic right ventricle (RV) face long-term complications that may impact their quality of life (QoL). Few data are available regarding the QoL in this patient group and its evolution over time. Methods: This study was performed in the SERVE trial's (identifier: NCT03049540) prospective cohort of patients (n = 100) with congenitally corrected transposition of the great arteries (TGA) or dextro-TGA after the atrial switch procedure and a longitudinal follow-up of 3 years. We aimed to describe the longitudinal QoL levels and their predictors. QoL was assessed using the Linear Analog Scale. QoL parameters were collected at baseline, after 12 months, and after 36 months, together with clinical parameters and a questionnaire assessing general self-efficacy (GSE). Results: The mean QoL on the Linear Analog Scale was 79.1 ± 13.6 at baseline, 75.5 ± 14.8 at 1 year, and 79.2 ± 13.6 at 3-year follow-up ( Conclusions: Patients with a systemic RV reported a stable good QoL during 3 years of follow-up. Exercise capacity and self-efficacy were the only independent predictors of QoL. Clinical Trial Registration: NCT03049540.

Identifiers

PMID40470125
PMCPMC12131024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.